Navigation Links
Arena and Eisai Announce Completion of Study Measuring Lorcaserin Concentrations in Human Cerebrospinal Fluid and Related Analyses
Date:8/2/2011

loss and maintenance of weight loss, in patients who are obese (BMI >30) or patients who are overweight (BMI >27) and have at least one weight-related co-morbid condition. Lorcaserin is a new chemical entity that is believed to act as a selective serotonin 2C receptor agonist. The serotonin 2C receptor is expressed in the brain, including the hypothalamus, an area believed to be involved in the control of appetite and metabolism. Arena has patents that cover lorcaserin in the United States and other jurisdictions that in most cases are capable of continuing into 2023 without taking into account any patent term extensions or other exclusivity Arena might obtain.

Arena submitted a New Drug Application (NDA) for lorcaserin to the FDA in December 2009, and the FDA issued a CRL in October 2010. Arena's wholly owned subsidiary, Arena Pharmaceuticals GmbH, has granted Eisai Inc. exclusive rights to market and distribute lorcaserin in the United States subject to FDA approval of the NDA for lorcaserin.

About Arena PharmaceuticalsArena is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs that target G protein-coupled receptors, an important class of validated drug targets, in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases.

Arena Pharmaceuticals® and Arena® are registered service marks of the company.

About Eisai Inc.Eisai Inc. was established in 1995 and is ranked among the top-25 US pharmaceutical companies (based on retail sales). The company began marketing its first product in the United States in 1997 and has rapidly grown to become a fully integrated pharmaceutical business. Eisai's areas of commercial focus include neurology, gastrointestinal disorders and oncology/critical care. The company serves as the US pharmaceutical operation of Eisai Co., Ltd., a research-based human health care (hhc)
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Arena Pharmaceuticals to Present at Four Upcoming Investor Conferences
2. Arena Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of APD125 for the Treatment of Insomnia
3. Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes
4. Arena Pharmaceuticals Announces Positive Phase 1a Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis and Initiates Phase 1b Clinical Trial
5. Arena Pharmaceuticals Initiates Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
6. Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd.
7. Arena Pharmaceuticals Presented Positive Phase 2a Clinical Trial Results of APD125 for the Treatment of Insomnia at 22nd Annual Meeting of the Associated Professional Sleep Societies
8. Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis
9. Critical Pharmaceuticals Enter Sustained Release hGH Arena
10. Arena Pharmaceuticals Announces Preliminary Results of Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
11. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Type 2 Diabetes Drug Candidate in Partnership with Ortho-McNeil-Janssen Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... , July 28, 2015  Insulet Corporation (NASDAQ: ... with its OmniPod ® Insulin Management System, today ... appointed to Insulet,s Board of Directors. Dr. ... experience to the Insulet Board. She currently serves as ... Diabetes Center, the world,s largest diabetes research center, diabetes ...
(Date:7/28/2015)... July 28, 2015  Express Scripts Holding Company (Nasdaq: ... attributable to Express Scripts stockholders of $600.1 million, or ... as detailed in Table 4, were $1.44 for the ... clear many companies across healthcare are validating the need ... Chief Executive Officer. "But, what matters most is how ...
(Date:7/28/2015)... PARK, Calif. , July 28, 2015 /PRNewswire/ ... medical device company that is providing innovative evidence-based ... announced the publication of the SENZA-RCT results in ... official Journal of the American Society of Anesthesiologists. ... a ground-breaking study that was the first to ...
Breaking Medicine Technology:Insulet Appoints Jessica Hopfield, PhD, to Board of Directors 2Insulet Appoints Jessica Hopfield, PhD, to Board of Directors 3Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 2Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 3Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 4Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 5Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 6Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 7Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 8Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 9Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 10Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 11Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 12Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 13Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 14Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 15Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 16Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 17Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 18Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 19Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 20Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 21Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 22Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 23Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 24Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 25Nevro Announces Publication of SENZA-RCT Results in Anesthesiology 2
... WMT ) announced today the availability of atorvastatin ... immediately for patients with valid prescriptions. The all-new generic ... Lipitor® provides a more affordable medication option for the millions ... to heart disease or are at risk for developing ...
...  Clinical Investigators for Arstasis, Inc., reported the results ... Meeting in San Francisco, demonstrating the Arstasis access ... arteries after cardiac catheterization procedures. The device creates ... the femoral artery through which catheterization procedures are ...
Cached Medicine Technology:Walmart Announces Generic Lipitor® (Atorvastatin Calcium Tablets) Available in Stores Today 2RECITAL Study Presents Excellent Outcomes and Rapid Patient Recovery With Revolutionary Femoral Access Procedure 2
(Date:7/29/2015)... ... , ... For the second year in a row, the management and staff ... fastest growing companies in Jacksonville. This annual list is compiled by the Jacksonville Business ... of Vast Bridges staffers were on hand to receive the award naming the company ...
(Date:7/29/2015)... ... 2015 , ... Fastline Publications, Inc., will be featured in ... Fastline is dedicated to quality agricultural advertising, both in print and online. In ... searchable agriculture equipment database in the world. The site has equipment listings worth ...
(Date:7/29/2015)... Mobile, AL (PRWEB) , ... July 29, 2015 , ... ... The directory will include the general contact information, website, types of plans administered, years ... submitted their business listing and have at least one plan with Employee Fiduciary. A ...
(Date:7/29/2015)... MO (PRWEB) , ... July 29, 2015 , ... ... of a decision from the Judicial Panel on Multidistrict Litigation (JPML), according to ... birth defects research at their website, the Zofran Birth Defects Lawsuit Center. , ...
(Date:7/29/2015)... ... July 29, 2015 , ... ... a global provider of life insurance, annuities, employee benefits and asset management, has ... inclusive sporting event taking place in Charlotte, North Carolina on October 2-4, ...
Breaking Medicine News(10 mins):Health News:Vast Bridges Continues Its Swift Growth 2Health News:Fastline Publications to Partner with American Farmer in Upcoming Episode Airing on RFD-TV 2Health News:Employee Fiduciary Launches Financial Advisor Directory 2Health News:Zofran Lawsuit News: Zofran Lawsuits Stayed, Awaiting MDL Decision 2Health News:Zofran Lawsuit News: Zofran Lawsuits Stayed, Awaiting MDL Decision 3Health News:Zofran Lawsuit News: Zofran Lawsuits Stayed, Awaiting MDL Decision 4Health News:MetLife Joins World T.E.A.M. Sports’ Adventure Team Challenge North Carolina as Presenting Sponsor 2Health News:MetLife Joins World T.E.A.M. Sports’ Adventure Team Challenge North Carolina as Presenting Sponsor 3
... The following is being,issued by The 100 Black Men of Atlanta, Inc.:, WHO: ... Atlanta Falcons Youth Foundation ... Girls Clubs of Metro Atlanta Retired ... health screening and fair for school-aged ...
... first quarter increased 80.6% compared to the first ... quarter 2007 to $23.8 million, - Gross profit for the first quarter increased ... first quarter of 2007 to $6.2 million ... history, HATBORO, Pa., April 30 InfoLogix, Inc.,(Nasdaq: IFLG ), a leading ...
... C. diff-associated disease (CDAD), otherwise known as severe intestinal ... pathogen, has been the subject of heightened concern in ... month by the federal Agency for Healthcare Research and ... diarrheal infections in U.S. hospitals between 2000 and 2005. ...
... ViroPharma Incorporated,(Nasdaq: VPHM ) reported today its financial results for ... December 31, 2007 include:, Development:, -- Notified sites participating ... in stem cell transplant patients that enrollment will be complete by ... Patient enrollment continued in Phase 3 study of maribavir in solid ...
... GXDX ), a specialized laboratory services provider, today announced,the ... scheduled to take place at the Four Seasons Hotel ... Dr. Tina Nova Bennett, President and CEO of Genoptix, ... Tuesday, May 13, 2008,beginning at approximately 9:20am PDT. They ...
... muscles may provide an ... for frown lines, SAN MATEO, Calif., April 30 ... it has acquired substantially all of the,assets of privately-held, ... technology rights for $12 million cash, plus,future royalties and ...
Cached Medicine News:Health News:Media Alert: 100 Black Men of Atlanta Host 3rd Annual Community Health Fair 2Health News:InfoLogix Announces First Quarter 2008 Financial Results 2Health News:InfoLogix Announces First Quarter 2008 Financial Results 3Health News:InfoLogix Announces First Quarter 2008 Financial Results 4Health News:InfoLogix Announces First Quarter 2008 Financial Results 5Health News:InfoLogix Announces First Quarter 2008 Financial Results 6Health News:InfoLogix Announces First Quarter 2008 Financial Results 7Health News:InfoLogix Announces First Quarter 2008 Financial Results 8Health News:InfoLogix Announces First Quarter 2008 Financial Results 9Health News:Report raises C. diff concerns; yeast-based probiotic shown to help significantly reduce recurrence 2Health News:ViroPharma Incorporated Reports First Quarter 2008 Financial Results 2Health News:ViroPharma Incorporated Reports First Quarter 2008 Financial Results 3Health News:ViroPharma Incorporated Reports First Quarter 2008 Financial Results 4Health News:ViroPharma Incorporated Reports First Quarter 2008 Financial Results 5Health News:ViroPharma Incorporated Reports First Quarter 2008 Financial Results 6Health News:ViroPharma Incorporated Reports First Quarter 2008 Financial Results 7Health News:ViroPharma Incorporated Reports First Quarter 2008 Financial Results 8Health News:ViroPharma Incorporated Reports First Quarter 2008 Financial Results 9Health News:ViroPharma Incorporated Reports First Quarter 2008 Financial Results 10Health News:Genoptix Announces Participation at the Bank of America 2008 Healthcare Conference 2Health News:BioForm Medical Acquires Facial Aesthetic Nerve Ablation Technology 2Health News:BioForm Medical Acquires Facial Aesthetic Nerve Ablation Technology 3Health News:BioForm Medical Acquires Facial Aesthetic Nerve Ablation Technology 4Health News:BioForm Medical Acquires Facial Aesthetic Nerve Ablation Technology 5
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: